Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus

Journal of Managed Care & Specialty Pharmacy
Liana K BillingsKathleen Wyne

Abstract

Type 2 diabetes (T2DM) is associated with significant impairment in health-related quality of life (HRQoL). A patient-centered collaborative approach is recommended to optimize clinical outcomes, including HRQoL, in this patient population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide effective glycemic control and have demonstrated beneficial effects on HRQoL and treatment satisfaction. Available once-weekly GLP-1 RAs may offer enhanced convenience compared with daily GLP-1 RAs and include exenatide extended-release (ER), dulaglutide, and semaglutide. This article reviews the impact of once-weekly GLP-1 RAs on HRQoL and treatment satisfaction in patients with T2DM. Compared with oral antihyperglycemic drugs, insulin, and daily GLP-1 RAs, once-weekly GLP-1 RAs offer benefits with regard to HRQoL and treatment satisfaction. These benefits appear to be largely mediated by relative drug effects on glycemic control, weight, and hypoglycemia. While there was not an overall class benefit of once-weekly GLP-1 RAs compared with daily GLP-1 RAs on HRQoL and treatment satisfaction, results suggested that once-weekly GLP-1 RAs may enhance certain elements of treatment satisfaction and increase willingness to continue trea...Continue Reading

References

Jul 1, 1984·MCN. the American Journal of Maternal Child Nursing·E Ahmann
Mar 3, 1998·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·F PouwerA N Brand
Aug 10, 1999·Diabetes/metabolism Research and Reviews·R R Rubin, M Peyrot
Dec 22, 2000·Spine·J E Ware
Sep 15, 2001·Journal of General Internal Medicine·K KroenkeJ B Williams
Sep 3, 2003·Diabetes Research and Clinical Practice·Ronette L KolotkinG Rhys Williams
Oct 30, 2003·Medical Care·Kurt KroenkeJanet B W Williams
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·F A Luscombe
Aug 4, 2007·Health and Quality of Life Outcomes·Louis S MatzaNicole Yurgin
Jul 4, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·J H BestM Peyrot
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
May 24, 2011·Journal of Diabetes and Its Complications·Paul GrantJohn Quin
Jul 16, 2016·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Qing QiaoKarel Kostev
Feb 6, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lei QinSusan Grandy
May 4, 2017·World Journal of Diabetes·Aikaterini TrikkalinouAndreas Melidonis
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Journal of Managed Care & Specialty Pharmacy
Michael HeileMichael Shannon
Journal of Managed Care & Specialty Pharmacy
Anthony CannonMichael Shannon
Journal of Managed Care & Specialty Pharmacy
Janet McGill
© 2022 Meta ULC. All rights reserved